Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
1 other identifier
observational
50
1 country
1
Brief Summary
Heart failure with preserved ejection fraction (HFpEF) was considered as a heterogeneous disease with multi-organ and multi-system design, which is related to various complications, such as hypertension, obesity and arteriosclerosis. Studies have found that hypertension and obesity are respectively associated with increased arterial stiffness. However, there is still no research investigating the the relationship between lipids distribution and arterial stiffness in HFpEF patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 21, 2020
CompletedFirst Submitted
Initial submission to the registry
October 11, 2020
CompletedFirst Posted
Study publicly available on registry
October 27, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedOctober 27, 2021
October 1, 2021
1.3 years
October 11, 2020
October 15, 2021
Conditions
Outcome Measures
Primary Outcomes (2)
Arterial stiffness
The baPWV(cm/s) of HFpEF patients
1 day after admission
adipose tissue distribution
The visceral fat area(cm\^2) in HFpEF patients
1 day after admission
Eligibility Criteria
Heart failure patients with preserved ejection fraction (HFpEF)
You may qualify if:
- Adult aged \>=18years old;
- Diagnosed with HFpEF.
- Diagnostic criteria including:
- left ventricular ejection fraction ≥50%;
- with the symptoms and/or signs of heart failure;
- BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL;
- at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction
You may not qualify if:
- LVEF less than 45% at any time;
- Severe liver failure; 3/Other causes of shortness of breath, such as severe pulmonary disease or severe chronic obstructive pulmonary disease;
- Primary pulmonary hypertension; 5.Severe valvular disease of the left heart; 6.Chronically bedridden or incapacitated; 7.Age \<18 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Chongqing Medical University
Chongqing, 400000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
October 11, 2020
First Posted
October 27, 2021
Study Start
September 21, 2020
Primary Completion
December 31, 2021
Study Completion
December 31, 2022
Last Updated
October 27, 2021
Record last verified: 2021-10
Data Sharing
- IPD Sharing
- Will not share